Satellos Bioscience has taken a significant step forward by submitting an IND application to the FDA for its Phase 2 trial of SAT-3247, aimed at addressing the urgent needs of patients with Duchenne Muscular Dystrophy (DMD). This move not only highlights the company’s commitment to developing innovative treatments but also positions it strategically within a competitive biotech landscape.
TORONTO–(BUSINESS WIRE)–Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), along with parallel regulatory filings in the United Kingdom, Europe, Serbia and Australia, to initiate a Phase 2 clinical trial of SAT-3247 in ambul
Source: Original Press Release
